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Proopiomelanocortin (POMC)-producing cells are present in both the anterior (AL) and intermediate (IL) lobes of the adult
rat pituitary. Both cell types are derived from a single embryonic rudiment, Rathke's pouch, and synthesize the same
hormone precursor, POMC, but differ in the pattern of precursor processing and regulation of peptide secretion. Here we
have used the reverse hemolytic plaque assay to determine the ontogeny of basal and regulated secretion by AL POMC
cells. Basal secretion of b-endorphin was ®rst observed at Embryonic Day 13.5 (e13.5), the age when POMC-derived peptides
were ®rst detected immunocytochemically. Peptide secretion stimulated by corticotropin releasing hormone (CRH; 1008
M) was ®rst detected at e15.5. The CRH-stimulated secretion involved two different components: (1) an increase in the
amount of hormone secreted per cell (increase in plaque size) as well as (2) an increase in the number of plaque-producing
cells. The greatest stimulation by CRH was observed at e16.5, a time when AL POMC mRNA levels increase signi®cantly
and when CRH neurons are ®rst detected immunocytochemically in the hypothalamus. CRH-stimulated secretion, but
not basal release, was inhibited by preincubation with dexamethasone (DEX; 1006 M) as early as e15.5, while the dopamine
agonist ergocryptine (ERG; 1006 M) did not alter basal or CRH-stimulated release at any age studied. These results demon-
strate that AL POMC cells are capable of hormone secretion as early as POMC peptides are ®rst detected immunocytochemi-
cally and that these cells respond in an adult-like manner to physiological regulators soon after their initial appearance.
Moreover, these responses remain unaltered during the early postnatal stress-nonresponsive period, suggesting that
de®cits at this time must lie at a level other than the corticotroph. Taken together, these results show that AL POMC
cells possess functional regulatory receptor systems prior to maturation of the hypothalamic±hypophyseal portal system.
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INTRODUCTION 1984, 1985; Childs and Burke, 1987). These cells form an
integral part of the hypothalamic±hypophysial±adrenal
The ®rst hormone-producing cells to differentiate in the axis and their secretory responses are, therefore, regulated
embryonic/fetal pituitary gland are the anterior lobe (AL) by hypothalamic factors as well as adrenal hormones (Axel-
corticotrophs (Conklin, 1968; Setalo and Nakane, 1972; Na- rod and Reisine, 1984). Corticotropin releasing hormone
kane et al., 1977; Watanabe and Daikoku, 1979) which arise (CRH) and adrenal glucocorticoids have been shown to be
in the rat between Embryonic Day 13 (e13) and e14 (Wata- the major physiological regulators of secretion from adult
nabe and Daikoku, 1979; Kachaturian et al., 1983, 1991; corticotrophs (Buckingham, 1979; Rosa et al., 1980; Vale et
Lugo et al., 1989). In the adult rat, corticotrophs comprise al., 1981, 1983; Rivier et al., 1982; Eberwine et al., 1987).
approximately 10% of the anterior pituitary cell population To date, few studies have investigated the development
(Moriarty, 1973; Leroux and Pelletier, 1984; Westlund et al., of the secretory capabilities of the fetal pituitary gland. Con-
ventional studies have used the presence of secretory gran-
ules as evidence of hormonal activity in these cells (Yos-1 Present address: Department of Neuroscience and Cell Biology,
hida, 1966; Svalander, 1974; Stoeckel et al., 1979; Dupouy,UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane,
1980). Ultrastructural studies in the rat by Svalander (1974)Piscataway, New Jersey 08854.
showed primordial granules in the AL at e14 and mature2 To whom correspondence should be addressed. Fax: 908-235-
4990. secretory granules at e15 suggesting the possibility of hor-
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monal release by AL cells as early as e14, although it cannot to speci®c regulatory factors with developmental age. Thus,
for example, glucocorticoid inhibition of CRH-stimulatedbe excluded that some hormone production, storage, and
ACTH secretion (Dupouy and Chatelain, 1984) may haverelease may occur without the formation of mature granules
been erroneously attributed solely to the AL POMC cells(Dupouy, 1980). For example, Shiino et al. (1978) have ob-
since the rat melanotrophs show similar responses tran-served hormone secretion from a cultured cell line derived
siently during development (Lugo and Pintar, 1996). Fur-from Rathke's pouch that lacks secretory granules.
ther, no study thus far has investigated the development ofEarly attempts to study pituitary secretion in vivo uti-
the secretory abilities of corticotrophs from the time of on-lized quite invasive procedures such as encephalectomy or
set of POMC gene expression. Finally, all in vivo and indecapitation of rat fetuses at late stages of development
vitro fetal as well as neonatal studies (Sato and Mains, 1986)(e16±e19) and subsequent examination of adrenal morphol-
on POMC cell secretion have measured POMC-derived pep-ogy a few days later (e21) (Chatelain et al., 1976; Cof®gny
tide release by radioimmunoassay (RIA) or bioassay fromand Dupouy, 1978; Chatelain and Dupouy, 1981). Adrenal
serum or media that includes the pooled secretion of manyatrophy was detected in experimental fetuses compared to
cells; thus, variability in individual cell responses cannotlittermate controls, which suggested that the hypotha-
be detected. For example, the adult male rat has a subpopu-lamic±pituitary adrenal axis may be functional a few days
lation of lactotrophs that appears stained upon prolactinprior to birth. In vitro, corticosterone secretion from adult
immunocytochemistry, but does not secrete prolactin un-adrenal glands increased when adrenals were co-incubated
less stimulated to secrete by estrogen treatment (Chen,with late (e21±e22) fetal pituitary glands, suggesting that
1987). These differences can only be observed with athe latter were capable of adrenocorticotropin (ACTH) re-
method that can detect secretion from single cells.lease in late gestation (Milkovic and Milkovic, 1962). More
The reverse hemolytic plaque assay (RHPA) has been de-
recently, a few studies have investigated the secretory capa- veloped and used to detect secretion by single cells in a
bilities of fetal pituitaries in a variety of mammalian spe- mixed cell population (Molinaro et al., 1981; Neill and
cies. These include in vivo studies in sheep (Wintour et al., Frawley, 1983). This method is based on antibody-directed,
1984; Norman and Challis, 1987) in which plasma ACTH complement-mediated lysis of protein A-coupled indicator
levels were determined by radioimmunoassay after injec- erythrocytes in proximity to the hormone secretors (Fraw-
tions of CRH or vasopressin or both as well as in vitro ley et al., 1986). This method has been successfully utilized
studies using whole pituitaries in organ culture (Dupouy to study the ontogeny of the secretory response of both
and Chatelain, 1984, rat) and in superfusion (Gibbs et al., somatotrophs (Frawley et al., 1985) and lactotrophs (Hoef-
1983; Blumenfeld and Jaffe, 1986, human; Hotta et al., 1988, ¯er et al., 1985; Chen, 1987). Thus, the time during develop-
rat), or dispersed cells from whole pituitaries in culture (Blu- ment at which basal release begins, the time of onset of
menfeld and Jaffe, 1986; Durand et al., 1986; Brooks et al., response to physiological regulators, and the nature of the
1987, sheep), while one study has examined secretion from individual cell responses can be investigated. Here we have
isolated lobes in superfusion (Gibbs et al., 1982, human). utilized the RHPA to investigate the ontogeny of basal,
While in general these studies suggest that the pituitary CRH- and glucocorticoid-regulated secretion by AL cortico-
gland may be functional at late fetal ages, there are a number trophs at the single-cell level beginning at the time of onset
of technical limitations. For example, since it is known that of POMC mRNA detection (e13; Lugo et al., 1989) to early
proopiomelanocortin (POMC) mRNA and POMC peptides postnatal ages (Postnatal Day 5, p5). Since responses to glu-
cocorticoids are expressed transiently during melanotrophare synthesized in (Civelli et al., 1982; Gee et al., 1983;
development (Scott and Pintar, 1993; Lugo and Pintar,Jingami et al., 1984; Pintar et al., 1984; Chen et al., 1986;
1996), the possibility that a response to dopamine agonistsLacaze-Masmonteil et al., 1987; Bronstein et al., 1992) and
might transiently occur in developing corticotrophs wasreleased from (Margioris et al., 1988; Eskeland et al., 1989)
also investigated. In addition, immunocytochemistry wasnonpituitary tissues, the source of plasma POMC peptides
performed following RHPA to investigate the following as-in in vivo studies is unknown. In vivo studies are compli-
pects of POMC cell differentiation: (1) the temporal rela-cated further by the presence of endogenous regulatory sub-
tionship between the onset of hormone accumulation (asstances. In addition, almost all in vitro fetal studies per-
detected by b-endorphin immunocytochemistry) and onsetformed thus far utilized whole pituitaries or cells dispersed
of secretion; (2) whether subpopulations of non-plaque-from whole pituitaries, and no attempt was made to isolate
forming corticotrophs exist; (3) whether there are subpopu-AL from neurointermediate lobes (NIL). This is an im-
lations of CRH responsive/unresponsive cells; (4) how theportant consideration when one considers that most of
percentage of secreting corticotrophs in whole glandsthese studies were conducted at ages in which both lobes
(e13.5±e15.5) or AL (e17.5±p5) changes during develop-contain and may release POMC-derived peptides. POMC-
ment.peptide products that are lobe-speci®c in the adult may be
present in both lobes during development (Pintar, 1984; MATERIALS AND METHODS
Pintar and Lugo, 1987), making interpretation of data ob-
Coupling of Protein A to Ovine Red Blood Cellstained from whole pituitaries very dif®cult. In addition, as
seen in the accompanying paper (Lugo and Pintar, 1996), Ovine erythrocytes (oRBC) in modi®ed Alsevier's solu-
tion (Hazelton Research Products, Inc.) were covalentlyPOMC cells within a single lobe may vary in their responses
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coupled to staphylococcal protein A (Sigma Chemical) using nates (p2, p3, and p5) were decapitated, the pituitary glands
removed, and AL and NIL separated (e17.5±p5). Whole pitu-chromium chloride according to the methods of Gronowicz
et al. (1976) and Neill and Frawley (1983). Brie¯y, 4 ml of itaries (e13±e16.5) and isolated AL and NIL from 10 to 18
animals (one to two litters) were pooled and placed in aoRBC (equivalent to 1 ml packed volume) was washed three
times by resuspension in normal saline and centrifuged for solution containing 0.03% collagenase (Worthington, type
III) in DMEM±0.1% BSA for 30±45 min at room tempera-5 min at 1000g (47C). Following washing, the oRBC were
incubated for 1 hr at 307C in an 11-ml solution containing ture and mixed three times every 15 min using a pipetman
(Rainin, P200). The cells were washed twice by centrifuga-1 ml of protein A (0.5 mg/ml) and 10 ml of chromium chlo-
ride (0.1 mg/ml) in normal saline (previously mixed). Subse- tion (1000g) and resuspension using DMEM±0.1% BSA, and
after the third centrifugation step the cells were resus-quently, the oRBC were washed once with normal saline,
twice with Dulbecco's modi®ed Eagle's media (DMEM; Ha- pended in the latter solution at a density of 1 1 106 cells/
ml and immediately assayed. Cell viability was assessed byzelton Research Products, Inc.)±0.1% bovine serum albu-
min (BSA; Sigma Chemical), resuspended as a 2% mixture trypan blue (0.1% in normal saline) exclusion (Leong et al.,
1985). Cell suspensions with 90% or greater cell survival(v/v) in the latter solution, and stored at 47C until use in
the plaque assay. Protein A-coupled oRBC remained viable were utilized in all assays.
for use in the plaque assay for up to 1 week. Just prior to
the plaque assay, an aliquot of the 2% suspension of protein
Reverse Hemolytic Plaque AssayA-coupled oRBC was washed once with DMEM±0.1% BSA
and resuspended to a 12% mixture in the latter solution This assay was performed in a 30-ml incubation chamber
constructed in the following manner. Glass slides were(Smith et al., 1986).
thoroughly washed with a soap solution (Alconox or Spar-
kleen; Fisher Scienti®c; 1 tsp/qt H2O), rinsed ®rst with tapDetermination of the Protein A Coupling to oRBC water then with dH2O, subbed in a 1% solution of dimethyl
sulfoxide (DMSO; Fisher Scienti®c) for 30 min, rinsed inSuccess of the protein A coupling to the oRBC was rou-
tinely assessed according to the procedures described by dH2O, and allowed to air dry. Subsequently, the slides were
dipped 31 (for 10 sec each) in a 0.2 mg/ml poly-L-lysineNeill and Frawley (1983). Brie¯y, 200 ml of the 2% mixture
of protein A-coupled oRBC were mixed with 40,000 cpm (Sigma Chemical Co.) solution followed by two quick rinses
in dH2O and air dried. After drying, two strips of Scotchof 125I-labeled human b-endorphin (50 ml) and 50 ml of b-
endorphin antiserum (1:50) (®nal concentration 1:300). (Pre- double stick tape were then placed approximately 20 mm
apart across the slide and a 24 1 60 mm untreated coverslipviously performed antiserum titration curves for the b-en-
dorphin antiserum had determined that a 1:300 dilution of was lowered onto the two pieces of tape (Cunningham and
Szenberg, 1968; Neill and Frawley, 1983).the antiserum was suf®cient to precipitate 70% of I125-la-
beled human b-endorphin using Staphylococcus aureus
(Calbiochem) for the antigen±antibody precipitations). The
Studies on Basal Secretion of POMC-Derivedcells were incubated for 3 hr at 377C and then centrifuged.
PeptidesThe oRBC pellet was washed three times (as described
above) and both the pellet and the supernatant were counted These and all subsequent reverse hemolytic plaque assay
experiments were carried out following the protocols de-using a gamma counter (Nuclear Chicago). Approximately
80% of the cpm were associated with the oRBC pellet. Con- scribed by Neill and Frawley (1983) and Smith et al. (1986)
unless otherwise stated. Equal volumes of whole pituitarytrols were run in which the b-endorphin antiserum was
omitted. In those experiments over 95% of the radioactive cells (e13±e16.5) or isolated AL cells (e17.5±p5) (1 1 106
cells/ml) and a 12% suspension of protein A-coupled oRBCcounts were associated with the supernatant. Alternatively,
the success of the coupling procedure was determined by were mixed and infused by capillary action into the plaque
assay chamber. The cells were allowed to attach to the slideperforming assays with AtT20/16-16 mouse anterior pitu-
itary corticotroph tumor cell lines, known to secrete low for 45 min in a 5% CO2±95% air humidi®ed incubator at
377C. After that time, unattached cells were removed fromlevels of POMC-derived peptide products basally and to be
responsive to CRH administration (Sabol, 1980). Formation the chamber by washing the chambers three times with
media. Washing was accomplished by placing freshof plaques around AtT20/16-16 cells following CRH, b-en-
dorphin antiserum and guinea pig complement addition de- DMEM±0.1% BSA (approximately 90 ml) on one side of the
chamber and drawing it through the slide with absorbenttermined a successful coupling procedure. Again, controls
involved omission of b-endorphin antiserum resulting in paper (Kimwipe). The chamber was then ®lled with a solu-
tion of DMEM±0.1% BSA containing b-endorphin antise-absence of plaque formation.
rum (1:50) (this concentration was optimal for plaque forma-
tion in pilot studies utilizing different b-endorphin antise-
Pituitary Cell Dispersion rum concentrations) and allowed to incubate for an
additional 45 min followed by infusion of the above solutionEmbryos (e13, e13.5, e15.5, e16.5, e17.5, e19.5, and e21)
isolated from decapitated timed-pregnant mothers and neo- together with guinea pig complement (Gibco; 1:25); this
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concentration was optimal for plaque formation and elimi-
nation of nonspeci®c lysis in pilot studies utilizing different
guinea pig complement concentrations. The chambers were
incubated for a further 2 hr after complement addition. The
plaque reaction begins at the time of antiserum infusion
into the chamber (Smith et al., 1986). Previous experiments
had shown that maximal percentage of plaques are obtained
after a 3-hr incubation period (Leong et al., 1985; Childs
and Burke, 1987), while maximal plaque size is obtained
after 4 hr. In the present experiments, a 3-hr incubation
period from the time of antiserum infusion was utilized
and was optimal for maximizing plaque development while
minimizing production of nonspeci®c hemolysis. The reac-
tion was stopped by washing the chamber twice with
DMEM±0.1% BSA followed by either ¯ooding the cham-
FIG. 1. CRH dose±response curve for corticotrophs. CRH dose±bers with freshly prepared 2% paraformaldehyde (Fisher Sci-
response curves were performed at e16.5 (whole pituitaries), e19.5,enti®c) in phosphate-buffered saline (PBS), pH 7, for 48 hr
and postnatal day 3 (p3) (isolated ALs). Represented here are the(for slides subsequently processed for immunocytochemis-
mean values obtained at e16.5. Statistically signi®cant (P £ 0.05)try) or by ¯ooding the chamber with a solution of 2% gluter-
increases in plaque areas above basal values were obtained with all
aldehyde (Fisher Scienti®c) in normal saline. While better CRH concentrations tested (1007, 1008, 1009, 10010 M). Each value
cell preservation was achieved with gluteraldehyde rather represents the mean { SEM of 25 plaques.
than with paraformaldehyde ®xation, the latter was neces-
sary for immunocytochemical signal detection of b-endor-
phin-related peptides (see the Immunocytochemistry sec-
tion). The slides ®xed with 2% paraformaldehyde (two sets ments were conducted utilizing different CRH concentra-
of basal and CRH-stimulated slides per age) were immersed tions in order to determine the concentration that resulted
in PBS, pH 7, for 2 additional days prior to removal of the in the largest increase in plaque area compared to basal
coverslips and processed for b-endorphin immunocyto- levels in AL cells (Fig. 1). CRH 1007 M (also used to investi-
chemistry, counterstained with hematoxylin (Fisher Scien- gate neonatal POMC secretion; Sato and Mains, 1986) pro-
ti®c), dehydrated in increasing alcohol concentrations (50, duced the largest plaques from all other CRH concentra-
70, 95, 100%), cleared in xylene, coverslipped using Per- tions tested and was used in all subsequent experiments.
mount (Fisher Scienti®c), and analyzed (see below). Those
®xed with gluteraldehyde (one to three additional sets per
Inhibition of POMC-Derived Peptide Release fromage) were coverslipped with 90% glycerol in PBS. Since only
Corticotrophsthe slides processed for immunocytochemistry were dehy-
drated, studies were conducted in order to determine
whether accurate plaque area comparisons could be made 1. Glucocorticoid inhibition of CRH (1007 M) stimula-
tion of secretion was investigated in whole pituitariesbetween dehydrated and nondehydrated slides. Two differ-
ent ages were tested (e15.5 and e16.5) and two different (e15.5±e16.5) and separated AL (e17.5±p5). Two sets of ex-
periments were carried out: (1) In one set, incubation withtreatments were performed. Duplicate slides of the same
treatment within the same experiment were subjected to dexamethasone (DEX, Sigma Chemical; 1006 M) began 45
min prior to the addition of b-endorphin antiserum andeither dehydration and coverslipping using Permount or
aqueous coverslipping with 90% glycerol in PBS. Twenty- CRH and continued throughout the length of the experi-
ment (a further 3 hr; Neill and Frawley, 1983). (2) In the®ve cells were counted in each slide (see below) and the
mean and the plaque area distribution were compared. Sta- second set of experiments, e17.5 or p2 AL were incubated
simultaneously with 1006 M DEX, CRH (1007 M) andtistical analysis of the means was performed using the two-
tailed Student's t test. The means of the slides subjected to b-endorphin antiserum (1:50). Initial experiments were per-
formed with isolated AL cells utilizing different DEX con-dehydration were not signi®cantly different (P £ 0.05) from
those coverslipped with 90% glycerol in PBS (data not centrations in order to determine the lowest DEX concen-
tration that produced maximal inhibition of the CRH stim-shown).
ulatory response before adopting 1006 M DEX as the
concentration to be used in all subsequent experiments
Studies on Stimulation of Secretion of POMC- (data not shown). The reaction was stopped by ¯ooding the
Derived Peptides chamber with a solution of 2% gluteraldehyde in normal
saline. The chambers were subsequently immersed in PBSStudies on stimulation of secretion were carried out iden-
tical to those on basal secretion but with the addition of for a few days followed by removal of the coverslip and re-
coverslipped and analyzed (see below).the secretagogue CRH together with the antiserum. Experi-
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2. Experiments were also carried out at e17.5 and e21 to oratories; 1 mg/ul, overnight) or incubation following the
plaque assay of e13 cells (an age at which no immunolabe-investigate inhibition of basal release by glucocorticoids. In
these studies incubation with DEX (1006 M) began 45 min ling is observed in vivo with b-endorphin antiserum at a
1:75 concentration). No immunostaining above backgroundprior to addition of b-endorphin antiserum and continued
throughout the duration of the experiment. was detected in either case (Fig. 2B).
3. The effect of the dopamine agonist 2-bromo-a-ergo-
cryptine (ERG, Sigma Chemical) on CRH stimulation of
Data AnalysisPOMC-related peptide secretion was investigated in whole
pituitaries (e16.5) or isolated AL cells (e19.5 and p3). Experi- Criteria for plaque identi®cation. The following crite-
ria (Childs and Burke, 1987) were used for plaque identi®ca-ments were carried out in the same manner as those for
secretagogue stimulation of POMC-related peptide release tion: 1. That there was at least 10 nm distance between the
pituitary cell and the ®rst row of oRBCs (a space slightlybut ERG (1006 M) was infused into the chambers 45 min
prior to CRH (1007 M) addition and incubation with ERG larger than the diameter of an oRBC); 2. that there was a
single cell in the center of the plaque; 3. that the secretingcontinued throughout the length of the experiment.
Ascorbic acid (1 mM) was included in all ERG-containing cell was viable (in our studies this constituted a cell that
excluded trypan blue; Leong et al., 1985).solutions to prevent its oxidation (Loef¯er et al., 1988).
Criteria for validity of the reverse hemolytic plaque
assay. The following criteria (Smith et al., 1986) were uti-
lized to determine the validity of the plaque assays: 1. Preab-Immunocytochemistry
sorption of the b-endorphin antiserum with rat b-endorphin
(Peninsula Laboratories; 1 mg/ul) overnight at 47C abolishedA variety of ®xation and immunocytochemical protocols
were tested. The following ®xation protocol gave reproduc- plaque formation completely; 2. omission of either antise-
rum or complement abolished plaque formation; 3. dilutionible, permanent attachment of oRBC onto the slides with-
out promoting lysis, while retaining b-EP antigenicity with of antiserum diminished and eventually abolished plaque
formation; 4. there was a dose±response between secreta-sensitivity comparable to that obtained in frozen embryonic
pituitary sections using either immuno¯uorescence or per- gogue (CRH) and plaque area.
Quantitation of the reverse hemolytic plaque assay.oxidase immunocytochemistry.
Following the plaque assay, two control and two CRH- 1. PLAQUE AREA. Plaques from trypan blue-excluding single
cells from randomly selected ®elds were measured by pro-treated chambers from each age were washed three times
with DMEM±0.1% BSA followed by ®xation with freshly jecting the ®elds onto a video screen (Sony) with a video
camera (DAGE MIT, Inc.) attached to a Leitz microscopeprepared 2% paraformaldehyde in PBS, pH 7, for 48 hr,
washed in PBS, pH 7, and the coverslips carefully removed (401 objective) and traced with a Houston Hipad, and cursor
interfaced with an IBM Bioquant Image Analysis Systemand subjected to b-endorphin immunocytochemistry with
the same antiserum used for the plaque assay at a concentra- IV. The plaque areas (which include the area of the cell
within it) were calculated with the stereometric analysistion of 1:75 rather than 1:50 as follows:
The slides were incubated for 30 min in a 0.05% solution program (Smith et al., 1986; Childs and Burke, 1987).
Plaques from 25 cells/slide were counted and averaged. Inof H2O2 to reduce endogenous peroxidase activity and then
washed in PBS, pH 7, containing Triton X-100 (0.3%) (HSB) order to determine reproducibility with the method of
counting, three slides were randomly chosen and recounted.several times. They were incubated overnight with the b-
endorphin antiserum (1:75) in HSB containing 5% normal The mean plaque size obtained in all three slides was virtu-
ally identical to what had been obtained previously (2goat serum (to block nonspeci®c binding of the secondary
antiserum). The following morning the slides were washed months earlier). Each individual experimental age was as-
sayed at least three times utilizing one to two litters (10±several times in HSB, incubated for 1 hr with HRP-labeled
goat anti-rabbit fab fragments of immunoglobin molecules 18 fetuses or neonates) per assay. Each experiment was sub-
jected to the two-tailed Student's t test in order to determine(1:100), washed in PBS, pH 7, several times, followed by
development for approximately 45 min with a freshly pre- the signi®cance of differences between the means among
the various treatments. The level of signi®cance was arbi-pared, ®ltered solution of 1 mM 3,3*-diaminobenzidine tet-
rahydrochloride containing 7 mM ammonium nitrate, 11 trarily chosen as P £ 0.05. While the absolute mean plaque
size of the various treatments from a particular age variedmM b-D-glucose, and 0.4 U/ml glucose oxidase. The slides
were washed several times in PBS, pH 7, followed by a 2- among experiments, the relative differences between the
various treatments within a speci®c age were consistent.min wash in dH2O, counterstained with hematoxylin, dehy-
drated in increasing alcohol concentrations followed by Analysis of variance (ANOVA) was used to determine differ-
ences within treatment as well as between treatmentsclearing in xylene, and coverslipped using Permount. An
example of a positively immunostained cell is shown in Fig. among ages. The signi®cance (P£ 0.05) of these differences
was analyzed using the Dunnett's t test. For this analysis,2A. Immunocytochemical controls included incubation of
cells following plaque assay with b-endorphin antiserum the mean value of three or more assays/treatment/age was
used, therefore n ⁄ 3.(1:75) previously absorbed with b-endorphin (Peninsula Lab-
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FIG. 2. b-Endorphin immunocytochemistry following plaque assay. Immunocytochemistry was performed on the cultures following
RHPA at all ages studied. An immunolabeled plaque-forming cell is shown in A. (B) An AL cell subjected to plaque assay, followed by
immunocytochemistry using b-endorphin antiserum preabsorbed with b-endorphin (see Materials and Methods). Note the absence of
immunolabeling in the plaque-forming cell. Edges of the plaques are denoted by arrows.
2. TOTAL PERCENTAGE OF CORTICOTROPHS IN AL AND THE age (see Fig. 3C). As expected, RHPA performed on dispersed
FRACTION (IN PERCENT) OF THESE THAT FORM PLAQUES UNDER pituitary cells at e13 did not detect any plaque-forming cells
BASAL AND CRH-STIMULATED CONDITIONS: After the control whether CRH (1007 M) was present (Fig. 3A) or absent (Fig.
and CRH-treated slides were processed for b-endorphin im- 3B). Plaque-forming pituitary cells were ®rst observed at
munocytochemistry and counterstained with hematoxylin e13.5 (Figs. 4A and 4B), which is the age when POMC-
(see above), the slides were analyzed under bright-®eld illu- derived peptide products are ®rst detected immunocyto-
mination using a Nikon microscope equipped with a 201 chemically (Fig. 4C; Lugo et al., 1989). At this age, CRH
objective. Random ®elds (about 500 cells/slide) in two (1007 M) did not affect either plaque size (compare Figs. 4A
slides/treatment/age were counted (Smith et al., 1986). To- and 4B; see also Fig. 5) or the percentage of b-endorphin
tal number of cells, total number of immunostained cells, immunostained corticotrophs stimulated to secrete (Table
as well as the number of plaque-forming immunostained 1); thus, the percentage of immunostained corticotrophs
cells were noted. The results are expressed as (1) percentage that produced plaques was approximately 50% in the ab-
of immunostained cells from total, that is, the percent of sence or presence of CRH (Table 1). CRH (1007 M)-stimu-
corticotrophs in whole pituitaries (e13.5±e15.5) or AL lated secretion was ®rst observed at e15.5 (compare Figs.
(e17.5±p5) and (2) the percentage of plaque-forming cells, 6B with 6C, see also Fig. 5). At this age, CRH increased the
that is, the percent of plaque-forming corticotrophs in plaque size twofold over basal (control) levels (Fig. 5), as
whole pituitaries (e13.5±e15.5) or isolated AL (e17.5±p5). well as the percent of b-endorphin immunostained plaque-
forming corticotrophs (30% control versus 50% in the pres-
ence of CRH (1007 M; Table 1). The stimulatory effect of
CRH on plaque size and percent of plaque-forming cells wasRESULTS
statistically signi®cant (P £ 0.05) and persisted throughout
all older prenatal (e16.5, e17.5, e19.5, e21) as well as postna-The ontogeny of basal and regulated secretion from AL
tal ages (p2 and p5) studied (Fig. 5; Table 1). CRH (1007 M)cells was studied using the RHPA to analyze pituitary cells
had its greatest stimulatory effect on individual cell secre-either isolated from whole glands at embryonic ages when
tion at e16.5 (Fig. 5). At this age, the average plaque sizethe vast majority of POMC immunopositive cells are local-
upon incubation with CRH was the largest in all agesized in the AL (e13±e16.5; Lugo et al., 1989) or from isolated
studied.AL beginning at e17.5 and continuing through early postna-
Although at all ages analyzed there was a subpopulationtal ages. Previous in situ hybridization studies (Lugo et al.,
of immunostained cells that never produced plaques, the1989) had demonstrated that POMC gene expression and
percentage of plaque-forming immunostained cells in-mRNA accumulation begins in cells of the AL at e13 and
that b-endorphin immunolabeling is virtually absent at this creased from 50% at e15.5 to nearly 70% at p5 (Table 1).
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FIG. 3. Absence of plaque formation at e13. No plaques are detected following reverse hemolytic plaque assay on dispersed pituitary
gland cells at e13 in the presence (A) or absence (B) of CRH (note cells at arrows). At this age no POMC-derived peptides are detected by
immunocytochemistry (C). Abbreviations: A, presumptive anterior lobe; I, presumptive intermediate lobe; PT, pars tuberalis.
Similar to the results of Childs and Burke (1987), we deter- basal (control) levels throughout all ages studied (e15.5±p5;
Fig. 5). The plaque areas following DEX pretreatment weremined that nearly 90% of the immunostained corticotrophs
formed plaques in assays utilizing adult rat AL cells (data relatively homogeneous and similar to control values (see
for example e17.5 response, Fig. 7). In those experiments innot shown).
The plaque-forming response of the corticotrophic cell which DEX (1006 M) was infused into the chambers in the
absence of CRH, plaque sizes were slightly smaller but notpopulation to CRH was heterogeneous. Some corticotrophs
do not form plaques in response to CRH stimulation even signi®cantly different from control values (data not shown).
A decrease in plaque area was not observed in experimentsat high doses (CRH 1007 M), others produced medium-sized
plaques, while others respond very vigorously and produced in which CRH (1007 M) and DEX (1006 M) were infused
simultaneously into the chambers (see for example e17.5plaques about 6±101 larger than those observed under con-
trol conditions (see for example e17.5; Fig. 7). This heteroge- responses in Fig. 8).
The ability of the dopamine agonist ERG (1006 M), aneity was observed in all ages in which a stimulatory re-
sponse to CRH was present (e15.5±p5). Under basal condi- known inhibitor of CRH-stimulated release in the IL (Loef-
¯er et al., 1988), to abolish CRH-stimulated POMC-derivedtions, the variability in plaque sizes, while still present, was
minimal (see Fig. 7, control). peptide release was tested at four ages (e16.5, e19.5, p3, and
p5). Cells were incubated with ERG (1006 M) for 45 minGlucocorticoid (DEX, 1006 M) inhibition of CRH (1007
M)-stimulated release was investigated beginning at e15.5, prior to CRH (1007 M) infusion. At no age did ERG (1006 M)
inhibit CRH (1007 M)-stimulated release (data not shown),since this was the earliest age in which CRH stimulation
of POMC-derived peptide release was detected. A 45-min although inhibition was detected in the IL (Lugo and Pintar,
1996).preincubation with DEX (1006 M) signi®cantly (P £ 0.05)
inhibited CRH (1007 M)-stimulated secretion. Following As mentioned previously, the percentage of AL cells con-
stituted by the POMC population was determined by b-this pretreatment, average plaque sizes were equivalent to
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FIG. 4. Onset of plaque formation at e13.5. Basal secretion of b-endorphin-related peptides was ®rst observed at e13.5 (B), which coincides
with the time when POMC peptides are ®rst detected by immunocytochemistry (C). POMC-related peptide immunoreactivity is also
observed in the developing diencephalon (C). CRH has no effect on plaque area at this age (A; see also Fig. 5). Abbreviations: A, presumptive
anterior lobe; I, presumptive intermediate lobe; PT, pars tuberalis; DI, diencephalon.
endorphin immunostaining. At e13, no immunostaining at p5 the percentage of corticotrophs in the AL had declined
to 26% and by adulthood it was 10±15%, similar to thatcould be detected in vivo or following plaque assay. From
e13.5 to e15.5 the percentage POMC-derived peptide-con- seen by others (Childs and Burke, 1987).
taining cells was quanti®ed from whole pituitary glands.
At e13.5, no POMC mRNA-containing or POMC immuno-
stained cell (Fig. 3C) is present in the IL. At e15.5 just a few DISCUSSION
cells of the IL contain POMC mRNA (Lugo et al., 1989)
and even fewer are immunolabeled (Fig. 6A). Therefore, the Our studies of the ontogeny of the secretory capabilities
of fetal rat AL POMC cells have demonstrated that thesenumber of immunolabeled cells in whole glands at these
ages re¯ects mostly AL cells. POMC cells comprise 13 and cells are capable of basal release of POMC-derived products
at the earliest ages in which these can be detected immuno-21% of the total pituitary cell population at e13.5 and e15.5,
respectively (Table 1). At later ages (e17.5 and older), the cytochemically (e13.5; Lugo et al., 1989) and, moreover,
that these cells have functional receptors for both CRH andAL and NIL could be isolated and assayed separately; there-
fore, the percentage of AL cells comprised by the cortico- glucocorticoids that allow them to respond to these physio-
logical regulators in an adult-like manner soon after theirtrophic population could be assessed directly. At e17.5, cor-
ticotrophs comprised approximately 40% of the population initial differentiation begins (e15.5).
The possibility remains that POMC-derived peptides mayof AL cells (Table 1). This high percentage remained
throughout late prenatal (e17.5±e21) and early postnatal (p2) be synthesized and released at e13 but at levels below the
sensitivity of RHPA (1 1 10018 mole; Smith et al., 1986).ages (Table 1). Nevertheless, a downward trend was ob-
served as postnatal development continued. For example, Nonetheless, the initial secretory activity of AL POMC
Copyright q 1996 by Academic Press, Inc. All rights of reproduction in any form reserved.
/ m4592$8075 12-19-95 09:01:16 dba Dev Bio
103Anterior Lobe POMC Cell Secretion
only detected an increase in plaque size above control val-
ues upon addition of CRH (1nM) but also an increase in
the percentage of plaque-producing cells from 6.6% under
control conditions to nearly 10% upon maximal CRH stim-
ulation. Responses to CRH stimulation in the present study
were present even at CRH concentrations of 0.1 nM. While
the actual CRH concentration in the fetal portal plasma
is unknown, these responses of isolated fetal AL cells to
nanomolar CRH concentrations are well within the physio-
logical ranges (0.1±1 nM) for CRH concentrations in the
adult rat portal blood (Gibbs and Vale, 1982). In agreement
with the results of Sato and Mains (1986) using neonatal
FIG. 5. Summary of the ontogeny of basal and regulated secretion rat AL cultures, the response of prenatal corticotrophs to
from corticotrophs. At e13.5 mean plaque sizes were unchanged in CRH does not reach a plateau even at CRH concentrations
the presence or absence of CRH. Statistically signi®cant (P £ 0.05) as high as 1007 M. Thus far, the reason for this observation
increases in plaque size following incubation with CRH were ob-
remains uncertain. At all ages studied, however, the POMCserved beginning at e15.5 and continued throughout all other older
population consists of cells at different stages of differentia-ages examined. DEX inhibition of CRH-stimulated b-endorphin
tion in which several parameters likely to affect their re-secretion from corticotrophs was ®rst observed at e15.5 and contin-
sponse to secretagogues are changing and may have notued throughout all ages examined. DEX inhibited CRH-stimulated
reached adult steady-state levels. These include: increasingb-endorphin secretion to levels statistically (P £ 0.05) similar to
control. Each bar represents the mean { SEM of three experiments levels of POMC mRNA/cell and of POMC peptide/cell and
(25 plaque areas/experiment). *Signi®cantly different from other a decreasing ratio of POMC hnRNA/POMC mRNA per cell
treatments. **Signi®cantly different from all other ages. (Lugo et al., 1989; Sato and Mains, 1985; Scott et al., 1990;
respectively). Although no information is available about
the ontogeny of CRH receptors (number/functional status),
it is conceivable that this parameter may also change as the
cells mature.cells (e13.5) appears to be primarily constitutive so that
addition of the physiological secretagogue CRH even at high The corticotroph response to CRH was heterogeneous.
Plaque sizes varied from areas identical to those observedconcentrations (1007 M) elicits no response. This lack of
responsiveness to secretagogues has also been reported for under control conditions to areas 6 to 10 times larger. Smith
et al. (1984), Chen (1987), and Childs and Burke (1987) haveyoung somatotrophs (Frawley et al., 1985) and young mela-
notrophs (Lugo and Pintar, 1996) under similar experimen-
tal conditions. Like corticotrophs, somatotrophs and mela-
notrophs become responsive to secretagogues, as shown by
TABLE 1increasing plaque sizes above basal values, 24±48 hr after
Effect of CRH on Corticotroph Plaque Formationonset of initial secretory activity. The lack of respon-
siveness of e13.5 corticotrophs to CRH stimulation could
Percentage ofbe due to either an absence of CRH receptors or immaturity
immunostained cells
of the signal transduction pathway. The recent cloning of Percentage ofwith plaques
the rat CRH receptor (Perrin et al., 1993) will allow the immunostained cells/
Age Control CRH total AL cellsontogeny of receptor gene expression to be determined di-
rectly, which would complement the assessment of func-
e13.5 48 49 13tional receptor activity reported here.
e15.5 30 50a 21CRH-stimulated POMC peptide secretion from cortico-
e17.5 33 53a 42b
trophs was ®rst observed at e15.5. This result agrees with e21 32 65a 40b
previous work that observed an increase in the release of p2 32 64a 37b
immunoreactive b-endorphin from superfused whole rat pi- p5 35 68a 26c
tuitary glands at e15.0 (Hotta et al., 1988). Our studies at
Note. The percentage of corticotrophs was calculated by countingthe single cell level have extended this observation by dem-
the number of immunolabeled cells following b-endorphin immu-onstrating that the increase in secreted hormone results
nocytochemistry from the total number of cells on slides previouslyfrom two different mechanisms: (1) an increase in the
subjected to reverse hemolytic plaque assays. The percentage ofamount of hormone secreted per cell (increase in plaque
plaque-forming corticotrophs was also determined. n  1000 cells
size) as well as (2) an increase in the number of plaque- for percentage of plaque-forming cells/treatment; n  2000 for per-
producing cells. Similar responses to CRH addition have cent of corticotrophs from total number of cells.
been observed in adult male rat AL cells subjected to RHPA a Statistically different from age-matched control (P 0.05) using
after 1 to 2 days in culture (Childs and Burke, 1987). In paired t test.
b Statistically different from ``c'' (P  0.05) using paired t test.agreement with our observations, the latter authors not
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FIG. 6. Response of POMC cells to secretory regulators at e15.5. The vast majority of immunoreactive cells at this age are localized in
the AL (6A). Plaque areas are larger in the presence (6B) versus the absence (6C) of CRH; CRH stimulation is inhibited by 45-min
preincubation with DEX (6D). Abbreviations: A, anterior lobe; I, intermediate lobe.
also reported plaques of different sizes upon incubation of mus (e16; under present staging criteria; Daikoku et al.,
1984). An interesting observation is that at e16.5 stimula-pituitary cells with secretagogue. Moreover, Childs and
Burke (1987) noted that potentiation by argenine vasopres- tion of secretion by addition of CRH (1007 M) results in the
largest average plaque area/cell of all ages studied. A similarsin (AVP) or angiotensin II (AII) of CRH-stimulated release
resulted in plaque areas with a more uniform size. These phenomenon has been observed in the sheep fetus in which
the response to CRH from short term pituitary cultures wasdata suggest that within a given pituitary cell population
differential release of hormonal stores must occur, so that higher on a per cell basis at e63 than at later ages (Durand
et al., 1986). In the rat, this period of increased response toupon basal conditions only a certain pool is released, while
upon stimulation, other stores are mobilized with appar- CRH roughly corresponds to the time at which signi®cant
increases in POMC mRNA levels in AL cells have beenently even larger stores available for release upon maximal
stimulation. Such a variation in the size of the ``readily detected by in situ hybridization (e17; Lugo et al., 1989)
and also coincides with the earliest immunocytochemicalreleasable pool'' of hormones has been shown for luteinizing
hormone during different stages of the estrous cycle of the detection of CRH-containing cells in the PVN (e16.0) and
of CRH-containing ®bers in the median eminence (e16.5,rat (Pickering and Fink, 1979).
The initial detection of a stimulatory effect by CRH upon Daikoku et al., 1984).
Glucocorticoid inhibition of CRH-stimulated peptide re-AL POMC cell secretion occurs at a time in which the CRH
content in the hypothalamus is very low (6.6 { 3.6 pg/ lease was observed beginning at the earliest age (e15.5) in
which a stimulatory effect by CRH could be detected andhypothalamus; Hotta et al., 1988) and it also precedes the
immunocytochemical detection of CRH-containing neu- persists throughout all older ages examined. Onset of the
inhibitory response correlates well with the ontogeny ofrons in the paraventricular nucleus (PVN) of the hypothala-
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FIG. 7. Plaque area distributions of isolated e17.5 AL cells following no treatment, CRH treatment, or CRH±DEX treatment (45-min
preincubation with DEX) have been plotted. Corticotrophs respond heterogeneously to CRH stimulation, while plaque sizes obtained
upon CRH±DEX treatment are not signi®cantly (P £ 0.05) different from basal values, have a similar size distribution and are more
homogeneous.
glucocorticoid receptor mRNA in the AL as detected by in (1987) using superfused adult AL and AL cell cultures, re-
spectively.situ hybridization (Cintra et al., 1993; Rene et al., 1994).
Our results also agree with observations obtained from pitu- Our studies also required DEX concentrations higher than
those utilized by Durand et al. (1986) in the sheep fetus anditary cultures of fetal sheep and neonatal lamb (Durand et
al., 1986), as well as from AL cultures from neonatal rats Sato and Mains (1986) in the neonatal rat. These observa-
tions may best be explained by the results of Abou-Samra(Sato and Mains, 1986).
In contrast to the observations of Dupouy and Chatelain et al. (1986) in which they noted a biphasic inhibitory effect
of glucocorticoids on CRH-stimulated release, so that the(1984) in the fetal rat and Durand et al. (1986) in the fetal
sheep and neonatal lamb, no statistically signi®cant inhibi- early phase of inhibition (45-min preincubation) as that
studied here requires signi®cantly higher concentrations oftion of basal secretion by DEX (as determined by plaque
size) was observed in the present studies, although plaque glucocorticoids than the late phase of inhibition ( 2 hr) as
that studied by Durand et al. (1986) and Sato and Mainssizes in the presence of DEX alone were slightly smaller
than those of control assays. These differences might be (1986). Nonetheless, studies by Scott and Pintar (1993) dem-
onstrated that DEX (1006 M) effects on P1 AL and NILexplained by considering the observations (Childs and
Burke; 1987) on the secretory activity of adult corticotrophs. POMC cells are mediated via type II (glucocorticoid) steroid
receptors. They showed that only the glucocorticoid recep-Preincubation with DEX (100 nM) not only decreased plaque
sizes to control values, but also decreased the number of tor antagonist RU 28362 (1006 and 1008 M) and not the
mineralocorticoid receptor antagonist ZK 91587 (1004 M)corticotrophs that produced plaques. Thus, while we did
not detect a decrease in average plaque size, the overall could counteract the inhibitory effect of DEX (1006 M) on
CRH (1007 M)-stimulated POMC gene transcription.amount of secretory peptide could be decreased due solely
to diminishing the number of corticotrophs that formed The response to simultaneous infusion of DEX (1006 M)
and CRH (1007 M) was studied in two age groups (e17.5 andplaques. Nonetheless, our results agree with those of Sato
and Mains (1986) in young neonatal rat AL cultures and p2). While the average plaque sizes were slightly smaller
than those obtained after infusion of CRH (1007 M) alone,with Widmaier and Dallman (1984) and Eberwine et al.
Copyright q 1996 by Academic Press, Inc. All rights of reproduction in any form reserved.
/ m4592$8075 12-19-95 09:01:16 dba Dev Bio
106 Lugo and Pintar
unknown factors encountered only by IL cells. Recent in
situ hybridization studies (Rene et al., 1994) are consistent
with this possibility. This is in contrast to the transient
glucocorticoid response observed in differentiating melano-
trophs (Scott and Pintar, 1993; Lugo and Pintar, 1996), sug-
gesting that expression of functional glucocorticoid recep-
tors is a general property of fetal pituitary POMC cells soon
after differentiation (see Lugo and Pintar, 1996).
In all fetal and neonatal ages investigated here, there was
a subpopulation of immunostained corticotrophs that never
formed plaques. The percentage of immunostained cells
that did not form plaques even in the presence of CRH (1007
M) decreased from 50% at e15.5 to about 30±35% at late
fetal and early neonatal ages. Whether the absence of plaque
formation is due to very small amounts or total absence
of hormonal release cannot be distinguished at this point.
Nonetheless, similar observations have been made on de-
FIG. 8. The inhibitory effect of DEX on CRH-stimulated release veloping lactotrophs (Chen, 1987), in adult gonadotrophs
requires preincubation with DEX. No signi®cant (P £ 0.05) de- (Smith et al., 1984), and in adult corticotrophs (Childs and
creases in mean plaque areas were observed if CRH and DEX were Burke, 1987) from rats. In neonatal lactotrophs (p5) as well
added simultaneously. Shown here are the responses of isolated as in adult male lactotrophs (Chen, 1987) the number ofe17.5 AL cells. *Signi®cantly different than **. Each bar represents
prolactin immunostained cells exceeded that of plaque-the mean { SEM of 25 values.
forming cells. At p5, only half of the immunostained lacto-
trophs formed plaques. In the adult male, 47% of the AL
population stained for Prl, while only 39% formed plaques.
On the other hand, in the adult male, this difference disap-the difference in plaque sizes was not statistically signi®-
cant. This response in the fetus and neonate varies from that peared after estrogen treatment of the animals. In addition,
a subpopulation of female gonadotrophs does not formobserved in the adult rat in which simultaneous addition of
CRH and DEX to cultured AL cells (Vale et al., 1983) or plaques during diestrous but appears to be responsive to
GnRH during proestrous when the estrogen levels in theof 1 nM CRH and 1007 M corticosterone to perifused AL
(Widmaier and Dallman, 1984) partially inhibited the stim- rat increase (Smith et al., 1984). Finally, Childs and Burke
(1987) also noted that a subpopulation of corticotrophsulatory effect of CRH. This discrepancy might only be ap-
parent rather than real. As mentioned earlier, Childs and (3%) in the adult male rat could be recruited to secrete
only upon incubation with a combination of lower doses ofBurke (1987) demonstrated that one of the effects of gluco-
corticoids is to reduce the percentage of plaques formed by CRH (100±500 pM) in combination with 1 nM AVP or AII.
Therefore, they suggested that perhaps a subpopulation ofcorticotrophs in addition to decreasing the size of plaques
formed by cells. It is therefore possible that while in our quiescent corticotrophs exists that may be recruited by AVP
or AII. Moreover, this recruitment involved an increase instudies the average size of the plaques remains statistically
the same, the percentage of cells producing plaques in the the number of plaque-forming cells while the average
plaque area was not larger than that obtained upon incuba-presence of glucocorticoids might be smaller, so that the
overall result would be a decrease in release of POMC-de- tion with CRH alone. Furthermore, in situ hybridization
studies using POMC probes as well as CRH receptor bindingrived hormones.
The effect of dopaminergic compounds upon fetal AL studies performed on adjacent sections of adult human pitu-
itaries indicated that approximately 35% of POMC mRNA-POMC cells was studied at various ages (e16.5, e19.5, p3,
and p5). At no time was a reduction in plaque size observed containing cells lack CRH receptors (Lopez et al., 1988).
This possibility can now be tested directly using probes toupon preincubation with ERG. These results are in
agreement with those of Sato and Mains (1986) in the post- the rat CRH receptor (Perrin et al., 1993).
Finally, it has been shown that the increase in plasmanatal rat and with observations of differential regulation of
POMC mRNAs levels (Chen et al., 1983) and POMC-de- corticosterone levels in response to stress is reduced during
the ®rst two weeks of life as compared to adult rat responsesrived peptide secretion (Vermes et al., 1980; Loef¯er et al.,
1988) in the adult pituitary gland. While the present studies (Guillet and Michaelson, 1978; Guillet et al., 1980; Walker
et al., 1986). In theory, any portion of the hypothalamic±do not directly address the possible presence/absence of do-
pamine D-2 receptors in fetal AL POMC cells, they indicate pituitary±adrenal (HPA) axis might be involved. The data
presented here suggest that although average plaque sizesthat no functional D-2 dopamine receptors are present in
developing corticotrophs and suggest that the development at p5 are slightly smaller than those observed at earlier ages,
the response of corticotrophs to CRH as determined by in-of functional dopamine D-2 receptors might be a character-
istic intrinsic to IL POMC cells or perhaps induced by yet crease in plaque area and in percentage of plaque-forming
Copyright q 1996 by Academic Press, Inc. All rights of reproduction in any form reserved.
/ m4592$8075 12-19-95 09:01:16 dba Dev Bio
107Anterior Lobe POMC Cell Secretion
corticotrophs is not much different from that observed at REFERENCES
earlier ages. These observations agree with those of Guillet
and Michaelson (1978) and Walker et al. (1986) in which Abou-Samra, A.-B., Catt, K. J., and Aguilera, G. (1986). Biphasic
they observed increases in plasma ACTH concentrations inhibition of adrenocorticotropin release by corticosterone in cul-
upon CRF injections throughout the ®rst 3 weeks of postna- tured anterior pituitary cells. Endocrinology 119, 972±977.
tal life and with the observations of Hotta et al. (1988) and Axelrod, J., and Reisine, T. D. (1984). Stress hormones: Their inter-
action and regulation. Science 224, 452±459.Sato and Mains (1986) in which they detected increased
Bartova, R. (1968). Functioning of the hypothalamic-pituitary-adre-POMC-derived peptide secretion from neonatal perifused
nal system during postnatal development in rats. Gen. Comp.pituitaries and cultured neonatal AL upon CRH addition,
Endocrinol. 10, 235±239.respectively. Taken together, the above results demonstrate
Blumenfeld, Z., and Jaffe, R. B. (1986). Hypophysiotropic and neuro-that this decrease in response to stress stimulation is not
modulatory regulation of adrenocorticotropin in the human pitu-due to a decrease in pituitary cell responsiveness to CRH.
itary gland. J. Clin. Invest. 7, 288±294.
Studies by others suggest that the levels responsible for this Bronstein, D. M., Schafer, M. K., Watson, S. J., and Akil, H. (1992).
stress-nonresponsive period are both above and below the Evidence that beta-endorphin is synthesized in cells in the nu-
pituitary level. For example, Bartova (1968) and Guillet et cleus tractus solitarius: Detection of POMC mRNA. Brain Res.
al. (1980) have shown that the adrenal gland response to 587, 269±275.
Brooks, A. N., Challis, J. R. G., and Norman, L.-J. (1987). PituitaryACTH stimulation decreases after p2 and increases again 2
and adrenal responses to pulsatile ovine corticotropin releasingweeks after birth. Walker et al. (1986) subjected animals to
factor administered to fetal sheep. Endocrinology 120, 2382±a variety of stressors (ether vapor, hypoxia, electroshock,
2388.and administration of urethane). They noted that while
Buckingham, J. C. (1979). The in¯uence of corticosteroids on theCRH injections increased ACTH levels in plasma at all ages
secretion of corticotrophin and the hypothalamic releasing hor-studied, the aforementioned stresses were not very effective
mones. J. Physiol. 286, 331±342.
prior to p14. They therefore suggested that the decreased Chatelain, A., Dubois, M. P., and Dupouy, J. P. (1976). Hypothala-
ability of HPA axis to respond to stress during the ®rst 2 mus and cytodifferentiation of the foetal pituitary gland: a study
weeks of postnatal life could be attributed to a defect at the in vivo. Cell Tissue Res. 169, 335±344.
hypothalamic level which they believe is probably due to Chatelain, A., and Dupouy, J. P. (1981). Activity of the pituitary-
adrenal system in rat fetuses subjected to encephalectomy in``insuf®cient stimulation of CRF-secreting neurons because
early or late stages of pregnancy. Neuroendocrinology 33, 148±of immature neurotransmitter pathways within the brain.''
152.In summary, we have, for the ®rst time, shown that corti-
Chen, C.-L. C., Chang, C. C., Krieger, D. T., and Bardin, C. W.cotrophs are capable of unregulated secretion beginning at
(1986). Expression and regulation of proopiomelanocortin-likethe ages where POMC products are ®rst detected immuno-
gene in ovary and placenta: comparison with the testes. Endocri-cytochemically. In addition, increases in POMC-derived
nology 118, 2382±2389.
peptide secretion due to CRH addition beginning at e15.5 Chen, H. T. (1987). Postnatal development of pituitary lactotropes
were due to both an increase in the amount of peptide se- in the rat measured by reverse hemolytic plaque assay. Endocri-
creted per cell as well as an increase in the percentage of nology 120, 247±253.
plaque-forming cells. The development of a response to glu- Childs, G. V., and Burke, J. A. (1987). Use of the reverse hemolytic
plaque assay to study the regulation of anterior lobe adrenocorti-cocorticoids paralleled the ontogenic development of a re-
cotropin (ACTH) secretion by ACTH releasing factor, argeninesponse to CRH, while a response to dopaminergic agonists
vasopressin, angiotensin II, and glucocorticoids. Endocrinologywas never elicited. Furthermore, the responses to CRH and
120, 439±444.DEX remained unchanged during the ®rst week of postnatal
Cintra, A., Solfrini, V., Bunnemann, B., Okret, S., Bortolotti, F.,life, demonstrating that de®cits leading to the stress-nonre-
Gustafsson, J.-A., and Fuxe, K. (1993). Prenatal development ofsponsive period must lie at a level other than the cortico-
glucocorticoid receptor gene expression and immunoreactivity
troph. In conclusion, the fetal rat pituitary gland is capable in the rat brain and pituitary gland: A combined in-situ hybridiza-
in vitro of POMC-derived peptide release at very early stages tion and immunocytochemical analysis. Neuroendocrinology 57,
of development and of adult-like responses to physiological 1133±1147.
regulators many days prior to birth. Civelli, O., Birnberg, N., and Herbert, E. (1982). Detection and
quantitation of proopiomelanocortin mRNA in pituitary and
brain tissues from different species. J. Biol. Chem. 257, 6783±
6787.ACKNOWLEDGMENTS Cof®gny, H., and Dupouy, J. P. (1978). The fetal adrenals of the
rat: correlations between growth, cytology and hormonal activity
with and without ACTH de®ciency. Gen. Comp. Endocrinol. 34,The authors are pleased to acknowledge advice from Jim Roberts
on different aspects of the plaque assay and are especially grateful 312±322.
Conklin, J. L. (1968). The development of the human fetal adenohy-to Ann-Judith Silverman for patient guidance during the statistical
analysis and for help in optimizing in vitro immunostaining follow- pophysis. Anat. Rec. 160, 79±92.
Cunningham, A. J., and Szenberg, A. (1968). Further improvementsing RHPA. This work was supported by HD-18592 and DA-08622.
Delia I. Lugo was supported by a fellowship from the Danforth± in the plaque technique for detecting single antibody-forming
cells. Immunology 14, 599±601.Compton Foundation.
Copyright q 1996 by Academic Press, Inc. All rights of reproduction in any form reserved.
/ m4592$8075 12-19-95 09:01:16 dba Dev Bio
108 Lugo and Pintar
Daikoku, S., Okamura, Y., Kawano, H., Tsuruo, Y., Maegawa, M., Kachaturian, H., Alessi, N. E., Munfakh, N., and Watson, S. J.
and Shibasaki, T. (1984). Immunohistochemical study on the de- (1983). Ontogeny of opioid and related peptides in the rat CNS
velopment of CRH-containing neurons in the hypothalamus of and pituitary: an immunocytochemical study. Life Sci. 33, 61±
the rat. Cell Tissue Res. 238, 539±544. 64.
Dupouy, J. P. (1980). Differentiation of MSH-containing, ACTH- Kachaturian, H., Kwak, S. P., Schafer, M. K. H., and Watson, S. J.
containing and LPH-containing cells in the hypophysis during (1991). Pro-opiomelanocortin mRNA and peptide co-expression
embryonic and fetal development. Int. Rev. Cytol. 68, 197±249. in the developing rat pituitary. Brain Res. Bull. 26, 195±201.
Dupouy, J. P., and Chatelain, A. (1984). In-vitro effects of corticoste- Lacaze-Masmonteil, T., de Ketzer, Y., Luton, J.-P., Kahn, A., and
rone, synthetic ovine corticotropin releasing factor and argenine Bertanaga, X. (1987). Characterization of proopiomelanocortin
vasopressin on the release of adrenocorticotropin by fetal rat pitu- transcripts in human nonpituitary tissues. Proc. Natl. Acad. Sci.
itary glands. J. Endocr. 101, 339±344. USA 84, 7261±7265.
Durand, P., Cathiard, A.-M., Dacheux, F., Naaman, E., and Saez, Leong, D. A., Lau, S. K., Sinha, Y. N., Kaiser, D. L., and Thorner,
J. M. (1986). In-vitro stimulation and inhibition of adrenocortico- M. O. (1985). Enumeration of lactotropes and somatotropes
tropin release by pituitary cells from ovine fetuses and lambs. among male and female pituitary cells in culture: Evidence in
Endocrinology 118, 1387±1394. favor of a mammosomatotrope subpopulation in the rat. Endocri-
Eberwine, J. H., Jonassen, J. A., Evinger, M. J. Q., and Roberts, J. L. nology 116, 1371±1378.
(1987). Complex transcriptional regulation by glucocorticoids Leroux, P., and Pelletier, G. (1984). Radioautographic study of bind-
and corticotropin-releasing hormone of proopiomelanocortin ing and internalization of corticotropin-releasing factor by rat
gene expression in rat pituitary cultures. DNA 6, 483±492. anterior pituitary corticotrophs. Endocrinology 114, 14±21.
Eskeland, N. L., Lugo, D. I., Pintar, J. E., and Schachter, B. S. (1989). Loef¯er, J.-P., Demeneix, B. A., Kley, N. A., and Hollt, V. (1988).
Stimulation of b-endorphin secretion by corticotropin-releasing Dopamine inhibition of proopiomelanocortin gene expression in
factor in primary rat Leydig cell cultures. Endocrinology 124, the intermediate lobe of the pituitary. Neuroendocrinology 47,
2914±2919.
95±101.
Frawley, L. S., Boockfor, F. R., and Hoef¯er, J. P. (1986). Focusing
Lopez, J. F., Mansour, A., Akil, H., Burke, S., Palkovits, M., Arato,
on hormone release. Nature 321, 793±794.
M., Schafer, M. K. H., and Watson, S. J. (1988). Localization of
Frawley, L. S., Hoef¯er, J. P., and Boockfor, F. R. (1985). Functional
POMC mRNA, glucocorticoid receptor mRNA and CRF recep-
maturation of somatotropes in fetal rat pituitaries: Analysis by
tors in human pituitaries. 18th Society for Neuroscience Meet-reverse hemolytic plaque assay. Endocrinology 116, 2355±2360.
ing, Toronto, Canada. [Abstract]
Gee, C. E., Chen, C.-L. C., Roberts, J. L., Thompson, R., and Watson,
Lugo, D. I., and Pintar, J. E. (1996). Ontogeny of basal and regulatedS. J. (1983). Identi®cation of proopiomelanocortin neurones in
proopiomelanocortin-derived peptide secretion from fetal andrat hypothalamus by in-situ cDNA-mRNA hybridization. Nature
neonatal pituitary intermediate lobe cells: Melanotrophs exhibit306, 374±376.
transient glucocorticoid responses during development. Dev.Gibbs, D. M., Stewart, R. D., Liu, J. H., Vale, W., Rivier, J., and
Biol. 173, 110±118.Yen, S. S. C. (1982). Effects of synthetic corticotropin-releasing
Lugo, D. I., Roberts, J. L., and Pintar, J. E. (1989). Analysis of proopi-factor and dopamine on the release of immunoreactive b-endor-
omelanocortin gene expression in the development of the ratphin/b-lipotropin and A-melanocyte-stimulating hormone from
pituitary gland. Mol. Endocrinol. 3, 1313±1324.human fetal pituitaries in-vitro. J. Clin. Endocrinol. Metab. 55,
Margioris, A. N., Grino, M., Protos, P., Gold, P. W., and Chrousos,1149±1152.
G. P. (1988). Corticotropin-releasing hormone and oxytocin stim-Gibbs, D. M., Stewart, R. D., Vale, W., Rivier, J., and Yen, S. S. C.
ulate the release of placental proopiomelanocortin peptides. J.(1983). Synthetic corticotropin-releasing factor stimulates secre-
Clin. Endocrinol. Metab. 66, 922±926.tion of immunoreactive b-endorphin/b-lipotropin and ACTH by
Milkovic, K., and Milkovic, S. (1962). Studies of the pituitary-adre-human fetal pituitaries in-vitro. Life Sci. 32, 547±550.
nocorticoid system in the fetal rat. Endocrinology 71, 799±802.Gibbs, D. M., and Vale, W. (1982). Presence of corticotropin releas-
Molinaro, G. A., Eby, W. C., and Molinaro, C. A. (1981). The reverseing factor-like immunoreactivity in hypophysial portal blood.
plaque-forming cell assay. Methods Enzymol. 73, 326±338.Endocrinology 111, 1418±1420.
Moriarty, G. C. (1973). Adenohypophysis: Ultrastructural cyto-Gronowicz, E., Coutinho, A., and Melchers, F. (1976). A plaque
chemistry. A review. J. Histochem. Cytochem. 21, 855±894.assay for all cells secreting Ig of a given type or class. Eur. J.
Nakane, P. K., Setalo, G., and Mazurkiewicz, J. E. (1977). The originImmunol. 6, 588±590.
of ACTH cells in rat anterior pituitary. Ann. N.Y. Acad. Sci. 297,Guillet, R., and Michaelson, S. M. (1978). Corticotropin respon-
201±204.siveness in the neonatal rat. Neuroendocrinology 27, 119±125.
Neill, J. D., and Frawley, L. S. (1983). Detection of hormone releaseGuillet, R., Saffran, M., and Michaelson, S. M. (1980). Pituitary-
from individual cells in mixed populations using a reverse hemo-adrenal response in neonatal rats. Endocrinology 106, 991±994.
lytic plaque assay. Endocrinology 112, 1135±1137.Hoef¯er, J. P., Boockfor, F. R., and Frawley, L. S. (1985). Ontogeny
Norman, L. J., and Challis, J. R. G. (1987). Synergism between sys-of prolactin cells in neonatal rats: Initial prolactin secretors also
temic corticotropin-releasing factor and argenine vasopressin onrelease growth hormone. Endocrinology 117, 187±195.
adrenocorticotropin release in-vivo varies as a function of gesta-Hotta, M., Shibasaki, T., Masuda, A., Imaki, T., Demura, H., Ohno,
tional age in the ovine fetus. Endocrinology 120, 1052±1058.H., Daikoku, S., Benoit, R., Ling, N., and Schizume, K. (1988).
Perrin, M. H., Donaldson, C. J., Chen, R., Lewis, K. A., and Vale,Ontogeny of pituitary responsiveness to corticotropin-releasing
W. W. (1993). Cloning and functional expression of a rat brainhormone in rat. Regul. Pept. 21, 245±252.
corticotropin releasing factor (CRF) receptor. Endocrinology 133,Jingami, H., Nakanishi, S., Imura, H., and Numa, S. (1984). Tissue
3058±3061.distribution of messenger RNA's coding for opioid peptide pre-
cursors and related RNA. Eur. J. Biochem. 142, 441±447. Pickering, A. J. M. C., and Fink, G. (1979). Variation in size of
Copyright q 1996 by Academic Press, Inc. All rights of reproduction in any form reserved.
/ m4592$8075 12-19-95 09:01:16 dba Dev Bio
109Anterior Lobe POMC Cell Secretion
the ``readily releasable pool'' of luteinizing hormone during the Smith, P. F., Luque, E. H., and Neill, J. D. (1986). Detection and
oestrous cycle of the rat. J. Endocr. 83, 53±59. measurement of secretion from individual neuroendocrine cells
Pintar, J. E. (1984). Molecular studies of pituitary gland differentia- using a reverse hemolytic plaque assay. Methods Enzymol. 124,
tion. In ``Gene Expression and Cell±Cell Interactions in the De- 443±465.
veloping Nervous System'' (J. M. Lauder and P. G. Nelson, Eds.), Stoeckel, M. E., Hindelang-Gertner, C., and Porte, A. (1979). Embry-
pp. 51±64. Plenum, New York. onic development and secretory differentiation in the pars tu-
Pintar, J. E., and Lugo, D. I. (1987). Proopiomelanocortin gene ex- beralis of the mouse hypophysis. Cell Tissue Res. 198, 465±476.
pression, prohormone processing, and secretion during rat pitu- Svalander, C. (1974). Ultrastructure of the fetal rat adenohypophy-
itary development. Ann. N.Y. Acad. Sci. 512, 318±327. sis. Acta Endocrinol. Suppl. 188, 1±114.
Pintar, J. E., Schachter, B. S., Herman, A. T., Durgerian, S., and Vale, W., Spiess, J., Rivier, C., and Rivier, J. (1981). Characterization
Krieger, D. T. (1984). Characterization and localization of proopi- of a 41-residue ovine hypothalamic peptide that stimulates secre-
omelanocortin messenger RNA in the adult rat testes. Science tion of corticotropin and b-endorphin. Science 213, 1394±1397.
225, 632±634. Vale, W., Vaughan, J., Smith, M., Yamamoto, G., Rivier, J., and
Rene, F., Hindelang, C., Stoeckel, M. E., and Felix, J. M. (1994). Rivier, C. (1983). The effects of synthetic ovine corticotropin-
Ontogeny of glucocorticoid and D2 receptors in the rat pituitary: releasing factor, glucocorticoids, catecholamines, neurohypo-
an in situ hybridization study. Mol. Cell. Endocrinol. 105, 65± physial peptides and other substances on cultured corticotropic
75. cells. Endocrinology 113, 1121±1131.
Rivier, C., Brownstein, M., Spiess, J., Rivier, J., and Vale, W. (1982). Vermes, I., Mulder, G. H., Smelik, P. G., and Tilders, F. J. H. (1980).
In vivo corticotropin-releasing factor-induced secretion of adre- Differential control of b-endorphin/b-lipotropin secretion from
nocorticotropin, b-endorphin and corticosterone. Endocrinology anterior and intermediate lobes of the rat pituitary gland in-vitro.
110, 272±278. Life Sci. 27, 1761±1768.
Rosa, P. A., Policastro, P., and Herbert, E. (1980). A cellular basis Walker, C. D., Perrin, M., Vale, W., and Rivier, C. (1986). Ontogeny
for the differences in regulation of synthesis and secretion of of the stress response in the rat: role of the pituitary and the
ACTH-endorphin peptides in anterior and intermediate lobes of hypothalamus. Endocrinology 118, 1445±1451.
the pituitary. J. Exp. Biol. 89, 215±237. Watanabe, Y. G., and Daikoku, S. (1979). An immunohistochemical
Sabol, S. L. (1980). Storage and secretion of b-endorphin and related study on the cytogenesis of adenohypophysial cells in fetal rats.
peptides by mouse pituitary tumor cells: regulation by glucocor- Dev. Biol. 68, 557±567.
ticoids. Arch. Biochem. Biophys. 203, 37±48. Westlund, K. N., Aguilera, G., and Childs, G. V. (1985). Quanti®ca-
Sato, S. M., and Mains, R. E. (1986). Regulation of adrenocortico- tion of morphological changes in pituitary corticotropes pro-
tropin/endorphin related peptide secretion in neonatal rat pitu- duced by in-vivo corticotropin-releasing factor stimulation and
itary cultures. Endocrinology 119, 793±801. adrenalectomy. Endocrinology 116, 439±445.
Scott, R. E. M., Autelitano, D. J., Lugo, D. I., Blum, M., Roberts, Westlund, K. N., Wynn, P. C., Chmielowiec, S., Collins, T. J., and
J. L., and Pintar, J. E. (1990). Developmental changes in levels of Childs, G. V. (1984). Characterization of a potent biotin-conju-
proopiomelanocortin intron A-containing heterogeneous nuclear gated CRF analog and the response of anterior pituitary cortico-
RNA and mature messenger RNA in the anterior and neurointer- tropes. Peptides 5, 627±634.
mediate lobes of the rat pituitary. Mol. Endocrinol. 4, 812±820. Widmaier, E. P., and Dallman, M. F. (1984). The effects of cortico-
Scott, R. E. M., and Pintar, J. E. (1993). Developmental regulation tropin-releasing factor on adrenocorticotropin secretion from per-
of proopiomelanocortin gene expression in the fetal and neonatal ifused pituitaries in-vitro: rapid inhibition by glucocorticoids.
rat pituitary. Mol. Endocrinol. 7, 585±596. Endocrinology 115, 2368±2374.
Setalo, G., and Nakane, P. K. (1972). Studies on the functional Wintour, E. M., Bell, R. J., Fei, D. T., Santhwell, C., Tregear, G. W.,
differentiation of cells in fetal anterior pituitary glands of rats and Xiaoming, W. (1984). Synthetic ovine corticotropin-releasing
with peroxidase-labelled antibody method. Anat. Rec. 172, 403± factor stimulates adrenocorticotropin release in the ovine fetus
404. over the last ®fth of gestation. Neuroendocrinology 38, 86±87.
Shiino, M., Ishikawa, H., and Rennels, E. G. (1978). Accumulation
Yoshida, Y. (1966). Electron microscopy of the anterior pituitary
of secretory granules in pituitary clonal cells derived from the
gland under normal and different experimental conditions. Exp.
epithelium of Rathke's pouch. Cell Tissue Res. 186, 53±61.
Pathol. 1, 439±454.Smith, P. F., Frawley, L. S., and Neill, J. D. (1984). Detection of LH
release from individual pituitary cells by the reverse hemolytic
Received for publication May 26, 1995plaque assay: Estrogen increases the fraction of gonadotropes re-
sponding to GnRH. Endocrinology 115, 2484±2486. Accepted October 3, 1995
Copyright q 1996 by Academic Press, Inc. All rights of reproduction in any form reserved.
/ m4592$8075 12-19-95 09:01:16 dba Dev Bio
